康华生物
(300841)
| 流通市值：68.14亿 | | | 总市值：75.07亿 |
| 流通股本：1.22亿 | | | 总股本：1.35亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,577,395,401.05 | 990,055,021.87 | 634,439,056.46 | 278,114,028.88 |
| 营业收入 | 1,577,395,401.05 | 990,055,021.87 | 634,439,056.46 | 278,114,028.88 |
| 二、营业总成本 | 959,259,718.87 | 586,246,100.92 | 363,213,245.23 | 166,597,332.57 |
| 营业成本 | 102,148,838.05 | 63,760,598.99 | 41,120,618.9 | 17,959,359.49 |
| 税金及附加 | 9,764,361.47 | 5,903,315.6 | 4,480,351.98 | 1,133,460.4 |
| 销售费用 | 495,444,122.89 | 270,260,847.6 | 175,106,092.4 | 78,388,151.54 |
| 管理费用 | 106,823,579.2 | 66,257,126.41 | 40,462,817.64 | 22,181,067.1 |
| 研发费用 | 253,025,564.84 | 185,927,273.77 | 105,813,253.73 | 48,657,680.12 |
| 财务费用 | -7,946,747.58 | -5,863,061.45 | -3,769,889.42 | -1,722,386.08 |
| 其中:利息费用 | 4,805,740.97 | 3,540,734.1 | 2,355,781.16 | 1,024,731.41 |
| 其中:利息收入 | 12,589,388.5 | 9,242,597.76 | 5,934,283.21 | 2,768,389.49 |
| 加:公允价值变动收益 | -31,597,059.93 | 10,943,588.77 | 15,443,223.92 | 13,053,201.93 |
| 加:投资收益 | 348,750 | - | - | - |
| 资产处置收益 | -186,829.86 | - | - | - |
| 资产减值损失(新) | -1,630,392.72 | 1,293,078.22 | -465,228.48 | -183,963.08 |
| 信用减值损失(新) | -9,837,646.58 | -7,275,210.13 | -10,157,555.88 | -7,608,956.94 |
| 其他收益 | 1,379,658.57 | -244,090.6 | 2,075,909.4 | 261,009.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 576,612,161.66 | 408,526,287.21 | 278,122,160.19 | 117,037,987.62 |
| 加:营业外收入 | 15,497.4 | 44,069.44 | 15,427.34 | 10,876.92 |
| 减:营业外支出 | 2,634,064.47 | 539,070.42 | 242,028.42 | 159,839.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 573,993,594.59 | 408,031,286.23 | 277,895,559.11 | 116,889,024.59 |
| 减:所得税费用 | 64,777,629.84 | 39,093,195.76 | 29,690,676.49 | 11,698,408.06 |
| 六、净利润 | 509,215,964.75 | 368,938,090.47 | 248,204,882.62 | 105,190,616.53 |
| 持续经营净利润 | 509,215,964.75 | 368,938,090.47 | - | 105,190,616.53 |
| 归属于母公司股东的净利润 | 509,215,964.75 | 368,938,090.47 | 248,204,882.62 | 105,190,616.53 |
| (一)基本每股收益 | 3.81 | 2.76 | 1.86 | 0.79 |
| (二)稀释每股收益 | 3.81 | 2.76 | 1.86 | 0.79 |
| 九、综合收益总额 | 509,215,964.75 | 368,938,090.47 | 248,204,882.62 | 105,190,616.53 |
| 归属于母公司股东的综合收益总额 | 509,215,964.75 | 368,938,090.47 | 248,204,882.62 | 105,190,616.53 |
| 公告日期 | 2024-03-30 | 2023-10-21 | 2023-08-23 | 2023-04-25 |
| 审计意见(境内) | 标准无保留意见 | | | |